Laboratory of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, 79 Gobong-ro, Iksan City, Jeollabuk-do, 54596, Republic of Korea; College of Veterinary Medicine and Agricultural Sciences, De La Salle Araneta University, 302 Victoneta Avenue, Potrero, Malabon City, 1475, Republic of the Philippines.
Laboratory of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, 79 Gobong-ro, Iksan City, Jeollabuk-do, 54596, Republic of Korea; Department of Urology, Mayo Clinic, Rochester, USA.
Microbes Infect. 2023 Jun;25(5):105101. doi: 10.1016/j.micinf.2023.105101. Epub 2023 Jan 16.
Since the emergence of the pandemic COVID19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the development of vaccines has been the prime strategy to control the disease transmission. Most of the developed vaccines target the spike protein, however, the emerging variants have alterations, particularly at the same region which may pose resistance to neutralizing antibodies. In this study, we explored the variable and conserved regions of SARS-CoV-2 as a potential inclusion in a multiple-target vaccine with the exploitation of Salmonella-based vector for oral mRNA vaccine against Delta and Omicron variants. Increased IgG and IgA levels imply the induction of humoral response and the CD4, CD8 and IFN-γ sub-population level exhibits cell-mediated immune responses. The degree of CD44 cells indicates the induction of memory cells corresponding to long-term immune responses. Furthermore, we assessed the protective efficacy of the vaccines against the Delta and Omicron variants in the hamster model. The vaccine constructs induced neutralizing antibodies and protected the viral-challenged hamsters with significant decrease in lung viral load and reduced histopathological lesions. These results reinforce the use of the conserved and variable regions as potential antigen targets of SARS-CoV-2 as well as the exploitation of bacteria-mediated delivery for oral mRNA vaccine development.
自严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)引起的大流行 COVID19 出现以来,疫苗的开发一直是控制疾病传播的主要策略。大多数开发的疫苗针对刺突蛋白,然而,新出现的变体具有改变,特别是在可能对中和抗体产生抗性的同一区域。在这项研究中,我们探索了 SARS-CoV-2 的可变区和保守区,作为一种潜在的多靶点疫苗的组成部分,利用基于沙门氏菌的载体开发针对 Delta 和 Omicron 变体的口服 mRNA 疫苗。IgG 和 IgA 水平的增加意味着诱导了体液免疫反应,CD4、CD8 和 IFN-γ 亚群水平则表现出细胞介导的免疫反应。CD44 细胞的程度表明诱导了与长期免疫反应相对应的记忆细胞。此外,我们在仓鼠模型中评估了疫苗对 Delta 和 Omicron 变体的保护效力。疫苗构建物诱导了中和抗体,并保护了受到病毒攻击的仓鼠,使肺部病毒载量显著降低,并减少了组织病理学损伤。这些结果证实了保守区和可变区作为 SARS-CoV-2 潜在抗原靶标的用途,以及细菌介导的递送在口服 mRNA 疫苗开发中的利用。